Q2 2026 net revenue rose to $37.7 million, up 9% from Q1 2026. Product growth was much stronger, with ZYNRELEF® net revenue up 35% and APONVIE® net revenue up 74% year-over-year. Overall, the quarter shows accelerating demand across key launches, supporting a moderately positive read-through for the business.
Q2 2026 net revenue rose to $37.7 million, up 9% from Q1 2026. Product growth was much stronger, with ZYNRELEF® net revenue up 35% and APONVIE® net revenue up 74% year-over-year. Overall, the quarter shows accelerating demand across key launches, supporting a moderately positive read-through for the business.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.35
